- This topic is empty.
May 29, 2013 at 7:49 pm #21318Catherine PooleKeymaster
Here’s the press release! Two GSK melanoma drugs get FDA approval
Release posted by Phila Business Journal/ Research Park Triangle Journal a few minutes ago.
GlaxoSmithKline received FDA approval for two melanoma drugs on Tuesday
Lauren K. Ohnesorge
Staff Writer- Triangle Business Journal
Two new drugs to treat advanced skin cancer, Tafinlar (dabrafenib) and Mekinist (trametinib), nabbed Food and Drug Administration approval on Tuesday. Both drugs have Triangle links, as does a test that received companion approval.
The drugs, developed by GlaxoSmithKline (NYSE: GSK), specifically treat melanoma, the leading cause of death from skin disease.
Tafinlar and Mekinist have each been approved to treat patients whose tumors express certain gene mutations. Additionally, a new genetic test, THxID BRAF has been approved to detect the mutations in patients.
The National Cancer Institute estimates nearly 77,000 Americans will be diagnosed with melanoma and nearly 9,500 will die from the disease in 2013.
GSK has its North American headquarters in Research Triangle Park. The THxID BRAF Kit is manufactured by bioMérieux of Grenoble, France. The company also has a Durham footprint.May 29, 2013 at 8:34 pm #60958LinnyParticipant
Hooray for Glaxo!
Having more options is a really good thing.May 29, 2013 at 8:37 pm #60959Catherine PooleKeymaster
Absolutely, happy day. The dual therapy of braf/mek has not been approved yet, but the application is in and should happen soon. These were approved as single agents. I will tell you more as I learn about it. ASCO is certainly going to focus on this breakthrough and melanoma will be in the limelight and deservingly so after 40 years of nothing much to offer.May 29, 2013 at 9:36 pm #60960LinnyParticipant The medical community is so darn close to getting a handle on this. Now if they can only figure out how it manages to outsmart these drugs.May 29, 2013 at 10:39 pm #60961LynnLucParticipant In the United States, the wholesale acquisition cost of Tafinlar is $7,600 for a 30-day supply and Mekinist will be $8,700 for a 30-day supply, according to a spokesperson for GlaxoSmithKline.
Read more: UPDATED: GlaxoSmithKline gains FDA OK on two genetically targeted melanoma drugs – FierceBiotech
http://www.fiercebiotech.com/story/glaxosmithkline-gains-fda-ok-two-genetically-targeted-skin-cancer-drugs/2013-05-29#ixzz2UivZHflIMay 30, 2013 at 12:00 am #60962TamilsParticipant Do MEK inhibitors do anything for BRAF wild type people? Maybe if you are BRAF WT but NRAS+? Maybe some MEK inhibitors only? I can’t seem to get a handle on this. I do see that this one is approved only for treatment of BRAF mutations, although that doesn’t necessarily mean it doesn’t have some effect elsewhere.May 30, 2013 at 12:50 am #60963Ferris2001Participant Another bullet for the arsenal, can’t complain about that!
- The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.